-
Synta Announces First Patient Treated in the GALAXY Trial™ a Phase 2b/3 Trial for Ganetespib in Advanced 2nd-line Non-small Cell Lung Cancer
Wednesday, July 20, 2011 - 8:06am | 210Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the first patient has been treated in a Phase 2b/3 clinical trial of ganetespib in combination with docetaxel in non-small cell lung cancer (NSCLC). Ganetespib is a potent inhibitor of heat shock protein 90 (Hsp90) that is...
-
Dynavax Phase 3 Demonstrates Superiority and Safety of HEPLISAV vs. Engerix-B
Wednesday, July 20, 2011 - 8:03am | 115Dynavax Technologies Corporation (NASDAQ: DVAX) today said that top-line data from its Phase 3 trial comparing HEPLISAV, an investigational hepatitis B virus (HBV) vaccine, to a currently marketed HBV vaccine, Engerix-B, demonstrated non-inferiority, superiority and the safety of HEPLISAV. The...
-
Sunesis Announces Publication of Phase 1b Data of Vosaroxin in Relapsed or Refractory Acute Leukemia
Wednesday, July 20, 2011 - 7:36am | 108Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the publication in Leukemia of data from a Phase 1b multi-center study of vosaroxin in relapsed or refractory leukemia. The results show that single-agent vosaroxin was well-tolerated, with a potent anti-leukemic effect in patients who...
-
Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120
Wednesday, July 20, 2011 - 7:32am | 102Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that it has successfully reached a key milestone in the non-clinical development of its live recombinant prostate cancer vaccine candidate, AEZS-120, for oral administration. The program, partially funded through a grant from the German...
-
AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen Commercial Portfolio and Achieve Cost Synergies
Wednesday, July 20, 2011 - 7:04am | 155AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million. The transaction is...
-
AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge to Strengthen
Wednesday, July 20, 2011 - 7:04am | 88AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million. The transaction is...
-
AMAG Pharmaceuticals and Allos Therapeutics Agree to Merge
Wednesday, July 20, 2011 - 7:03am | 88AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that they have entered into a definitive merger agreement under which the companies will combine in an all-stock merger with a total equity value of approximately $686 million. The transaction is...
-
Rodman & Renshaw Reiterates Market Outperform and PT of $2 on EpiCept
Wednesday, July 20, 2011 - 3:05am | 48Rodman & Renshaw reiterated its Market Outperform rating on EpiCept (NASDAQ: EPCT). At the same time, the rating agency left its price target on the company's stock unchanged at $2. On Tuesday, EPCT added 6% to its value to finish the day at $0.53.
-
Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows
Wednesday, July 20, 2011 - 1:51am | 3102Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Tuesday's trading session (listed from highest total volume to lowest): 1) Apple (NASDAQ: AAPL): Shares of Apple...
-
Technology Companies Outshine Among Large Cap Growth Stocks
Tuesday, July 19, 2011 - 4:43pm | 97Large technology companies such as those in Nasdaq 100 (QQQ) (COMP) have been doing exceptionally well in the past five years. They out performed large[...more...] (COMP) (QQQQ) (AAPL) (ORCL) (MSFT) (GOOG) (INTC) (CSCO) (AMZN) (...
-
Options Brief: Arena Pharmaceuticals
Tuesday, July 19, 2011 - 3:37pm | 85Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are higher on the session by 1.46%, trading at $1.39. Overall call volume is now running at 3.96x the daily average, with 78% of all calls traded being purchases on the offer. 2,846 contracts have traded on the session so far. Arena Pharmaceuticals...
-
Alexion Pharmaceuticals Hits New 52-Week Highs at $52.67
Tuesday, July 19, 2011 - 11:20am | 76Many traders and investors see the 52-week high or low as an important indicator. Stocks that have a long-term trend in a certain direction are likely to continue, as that trend is the path of least resistance. In this case, shares of Alexion Pharmaceuticals (NASDAQ: ALXN) are hitting new 52-week...
-
CEL-SCI Corporation and Teva Pharmaceuticals Expand Licensing Agreement
Tuesday, July 19, 2011 - 10:54am | 175CEL-SCI Corporation (NYSE: CVM) announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries (NASDAQ: TEVA) for its cancer drug Multikine. Under the agreement, Teva's exclusive license to market and distribute Multikine, the Company's investigational Phase III...
-
Deutsche Bank Comments on Regeneron Pharmaceuticals
Tuesday, July 19, 2011 - 10:14am | 118Deutsche Bank has released a report on Regeneron Pharmaceuticals (NASDAQ: REGN) highlighting strengths. In the report, Deutsche Bank wrote, "Last night Novartis announced its 2Q'11 numbers for Lucentis. Lucentis EU sales in 2Q stood at $541M vs. $444M in 1Q'11 (up 22% qoq). The excellent growth in...
-
Morning Market Losers
Tuesday, July 19, 2011 - 9:57am | 104Neostem Inc (AMEX: NBS) dipped 23.48% to $1.01 at 9:55 am. NBS priced an underwritten public offering of 13,750,000 units at $1.20 per unit. Star Bulk Carriers Corp (NASDAQ: SBLK) fell 17.91% to $1.65. SBLK intends to offer and sell 16,500,000 common shares in an underwritten public offering....